|
JP2791732B2
(ja)
|
1992-04-02 |
1998-08-27 |
小野薬品工業株式会社 |
3′−アミノ−2′−ヒドロキシアセトフェノンの製造方法
|
|
US6143749A
(en)
|
1995-06-07 |
2000-11-07 |
Abbott Laboratories |
Heterocyclic substituted cyclopentane compounds
|
|
WO2003070739A1
(en)
|
2002-02-19 |
2003-08-28 |
Cv Therapeutics, Inc. |
Partial and full agonists of a1 adenosine receptors
|
|
US20040043959A1
(en)
|
2002-03-04 |
2004-03-04 |
Bloom Laura A. |
Combination therapies for treating methylthioadenosine phosphorylase deficient cells
|
|
US20040138238A1
(en)
|
2002-08-08 |
2004-07-15 |
Dhanoa Dale S. |
Substituted aminopyrimidine compounds as neurokinin antagonists
|
|
CA2509406C
(en)
|
2002-12-23 |
2012-07-03 |
Janssen Pharmaceutica N.V. |
Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
|
|
US7612078B2
(en)
|
2003-03-31 |
2009-11-03 |
Epix Delaware, Inc. |
Piperidinylamino-thieno[2,3-D] pyrimidine compounds
|
|
MXPA06013250A
(es)
|
2004-05-14 |
2007-02-28 |
Abbott Lab |
Inhibidores de quinasa como agentes terapeuticos.
|
|
JP4545196B2
(ja)
|
2005-01-19 |
2010-09-15 |
メルク・シャープ・エンド・ドーム・コーポレイション |
有糸分裂キネシン阻害剤
|
|
GB0713602D0
(en)
|
2007-07-12 |
2007-08-22 |
Syngenta Participations Ag |
Chemical compounds
|
|
TWI389913B
(zh)
|
2008-09-08 |
2013-03-21 |
Lg Life Sciences Ltd |
并合雜環化合物
|
|
WO2010041366A1
(ja)
|
2008-10-06 |
2010-04-15 |
日本電気株式会社 |
無線通信装置、無線通信システム、無線通信装置の制御方法、及び記録媒体
|
|
WO2010066629A2
(en)
|
2008-12-09 |
2010-06-17 |
F. Hoffmann-La Roche Ag |
Novel azaindoles
|
|
JP2011026305A
(ja)
|
2009-06-24 |
2011-02-10 |
Daiichi Sankyo Co Ltd |
イミダゾールカルボニル化合物を含有する医薬組成物
|
|
CN102471291B
(zh)
|
2009-08-20 |
2015-04-22 |
拜尔农作物科学股份公司 |
用作杀螨剂和杀昆虫剂的3-三唑基苯基取代的硫化物衍生物
|
|
AU2010289321A1
(en)
|
2009-09-04 |
2012-04-05 |
The Regents Of The University Of Michigan |
Compositions and methods for treatment of leukemia
|
|
GB201004200D0
(en)
*
|
2010-03-15 |
2010-04-28 |
Univ Basel |
Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
|
|
US9586961B2
(en)
|
2010-07-09 |
2017-03-07 |
Leo Pharma A/S |
Homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
|
|
AU2011341441A1
(en)
|
2010-12-03 |
2013-06-20 |
Epizyme, Inc. |
Modulators of histone methyltransferase, and methods of use thereof
|
|
EP2646454B1
(en)
|
2010-12-03 |
2015-07-08 |
Epizyme, Inc. |
7-deazapurine modulators of histone methyltransferase, and methods of use thereof
|
|
GB201021623D0
(en)
|
2010-12-21 |
2011-02-02 |
Isis Innovation |
Detection of acute myeloid leukaemia
|
|
WO2013014162A1
(en)
|
2011-07-28 |
2013-01-31 |
Cellzome Limited |
Heterocyclyl pyrimidine analogues as jak inhibitors
|
|
WO2013018404A1
(ja)
|
2011-08-01 |
2013-02-07 |
オリンパスメディカルシステムズ株式会社 |
挿入部形状表示装置
|
|
CN103889983B
(zh)
|
2011-09-14 |
2015-12-09 |
普罗克西梅根有限公司 |
酶抑制剂化合物
|
|
WO2014035140A2
(en)
|
2012-08-30 |
2014-03-06 |
Kainos Medicine, Inc. |
Compounds and compositions for modulating histone methyltransferase activity
|
|
CN103664991B
(zh)
|
2012-09-19 |
2016-12-28 |
中国科学院福建物质结构研究所 |
噻吩[2,3‑d]嘧啶衍生物、其制备方法及其用途
|
|
MX2015006191A
(es)
|
2012-11-16 |
2015-08-10 |
Merck Sharp & Dohme |
Inhibidores de purina de fosfatidilinositol 3-quinasa delta humana.
|
|
US9908887B2
(en)
|
2012-12-21 |
2018-03-06 |
Epizyme, Inc. |
PRMT5 inhibitors and uses thereof
|
|
US9604930B2
(en)
|
2012-12-21 |
2017-03-28 |
Epizyme, Inc. |
Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof
|
|
JP2016505002A
(ja)
|
2012-12-21 |
2016-02-18 |
エピザイム,インコーポレイティド |
ジヒドロイソキノリンまたはテトラヒドロイソキノリンを含有するprmt5阻害剤およびその使用
|
|
AU2014249233A1
(en)
|
2013-03-13 |
2015-09-24 |
The Regents Of The University Of Michigan |
Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
|
|
US10329270B2
(en)
|
2013-10-21 |
2019-06-25 |
Merck Patent Gmbh |
Heteroaryl compounds as BTK inhibitors and uses thereof
|
|
US9708568B2
(en)
|
2014-05-06 |
2017-07-18 |
The Procter & Gamble Company |
Fragrance compositions
|
|
US20170119769A1
(en)
|
2014-06-10 |
2017-05-04 |
The Trustees Of The University Of Pennsylvania |
Scaffolds for inhibitors of menin-mll interactions
|
|
WO2015200680A2
(en)
|
2014-06-25 |
2015-12-30 |
Epizyme, Inc. |
Prmt5 inhibitors and uses thereof
|
|
CN105330698B
(zh)
|
2014-07-04 |
2019-05-28 |
齐鲁制药有限公司 |
螺环芳基磷氧化物和硫化物
|
|
JP6487527B2
(ja)
*
|
2014-07-04 |
2019-03-20 |
チル ファーマシューティカル カンパニー リミテッド |
スピロ環アリールリン酸化物及びアリールリン硫化物(spirocyclic aryl phosphorus oxide and aryl phosphorus sulfide)
|
|
USRE49687E1
(en)
|
2014-09-09 |
2023-10-10 |
The Regents Of The University Of Michigan |
Thienopyrimidine and thienopyridine compounds and methods of use thereof
|
|
GB201416352D0
(en)
*
|
2014-09-16 |
2014-10-29 |
Shire Internat Gmbh |
Spirocyclic derivatives
|
|
EP3207030A4
(en)
|
2014-10-14 |
2018-06-06 |
Merck Sharp & Dohme Corp. |
Inhibitors of the renal outer medullary potassium channel
|
|
US10526341B2
(en)
|
2014-11-19 |
2020-01-07 |
Memorial Sloan-Kettering Cancer Center |
Thienopyrimidines and uses thereof
|
|
PL3233857T3
(pl)
|
2014-12-18 |
2020-07-27 |
Takeda Pharmaceutical Company Limited |
Stałe postacie skondensowanych heteroaromatycznych pirolidynonów
|
|
CN105732636B
(zh)
|
2014-12-30 |
2020-04-21 |
广东东阳光药业有限公司 |
杂芳化合物及其在药物中的应用
|
|
EA031895B1
(ru)
|
2015-02-24 |
2019-03-29 |
Пфайзер Инк. |
Замещенные нуклеозидные производные, полезные в качестве агентов против рака
|
|
TWI703150B
(zh)
|
2015-06-04 |
2020-09-01 |
美商庫拉腫瘤技術股份有限公司 |
用於抑制menin及mll蛋白之交互作用的方法及組合物
|
|
WO2016197027A1
(en)
|
2015-06-04 |
2016-12-08 |
Kura Oncology, Inc. |
Methods and compositions for inhibiting the interaction of menin with mll proteins
|
|
TWI730980B
(zh)
|
2015-08-26 |
2021-06-21 |
比利時商健生藥品公司 |
使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
|
|
BR112018012707A2
(pt)
|
2015-12-22 |
2019-01-29 |
Vitae Pharmaceuticals Inc |
inibidores da interação de menin-mll
|
|
AU2017212572A1
(en)
|
2016-01-26 |
2018-08-23 |
Memorial Sloan-Kettering Cancer Center |
Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia
|
|
WO2017161028A1
(en)
|
2016-03-16 |
2017-09-21 |
Kura Oncology, Inc. |
Substituted inhibitors of menin-mll and methods of use
|
|
US10752639B2
(en)
|
2016-03-16 |
2020-08-25 |
Kura Oncology, Inc. |
Bridged bicyclic inhibitors of menin-MLL and methods of use
|
|
CN109415337B
(zh)
|
2016-05-02 |
2022-01-18 |
密执安大学评议会 |
作为多发性内分泌腺瘤蛋白抑制剂的哌啶
|
|
WO2017207387A1
(en)
|
2016-05-31 |
2017-12-07 |
Bayer Pharma Aktiengesellschaft |
Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
|
|
ES2831084T3
(es)
|
2016-06-10 |
2021-06-07 |
Vitae Pharmaceuticals Inc |
Inhibidores de la interacción menina-MLL
|
|
WO2018024602A1
(en)
|
2016-08-04 |
2018-02-08 |
Bayer Aktiengesellschaft |
2,7-diazaspiro[4.4]nonanes
|
|
JP7071644B2
(ja)
|
2016-09-06 |
2022-05-19 |
株式会社スリーボンド |
熱硬化型導電性接着剤
|
|
US12084462B2
(en)
|
2016-09-14 |
2024-09-10 |
Janssen Pharmaceutica Nv |
Spiro bicyclic inhibitors of menin-MLL interaction
|
|
TWI753016B
(zh)
|
2016-09-14 |
2022-01-21 |
比利時商健生藥品公司 |
Menin-mll相互作用之稠合二環抑制劑
|
|
AU2017326487B2
(en)
|
2016-09-14 |
2021-08-05 |
Janssen Pharmaceutica Nv |
Spiro bicyclic inhibitors of menin-MLL interaction
|
|
CA3033239A1
(en)
|
2016-09-14 |
2018-03-22 |
Janssen Pharmaceutica Nv |
Spiro bicyclic inhibitors of menin-mll interaction
|
|
CN118359610A
(zh)
|
2016-09-16 |
2024-07-19 |
生命医药有限责任公司 |
Menin-mll相互作用的抑制剂
|
|
WO2018106820A1
(en)
|
2016-12-07 |
2018-06-14 |
Kura Oncology, Inc. |
Methods of promoting beta cell proliferation
|
|
WO2018106818A1
(en)
|
2016-12-07 |
2018-06-14 |
Kura Oncology, Inc. |
Methods of promoting beta cell proliferation
|
|
KR102513564B1
(ko)
|
2016-12-15 |
2023-03-22 |
얀센 파마슈티카 엔.브이. |
메닌-mll 상호작용의 아제판 억제제
|
|
EA201991448A1
(ru)
|
2017-01-06 |
2019-12-30 |
Янссен Фармацевтика Нв |
Азепановые ингибиторы взаимодействия менин-mll
|
|
CN108456208B
(zh)
|
2017-02-22 |
2021-04-16 |
广州市恒诺康医药科技有限公司 |
氮杂螺环类化合物及其制备方法和应用
|
|
CN110691779B
(zh)
|
2017-03-24 |
2023-10-10 |
库拉肿瘤学公司 |
治疗血液系统恶性肿瘤和尤因肉瘤的方法
|
|
US11542248B2
(en)
|
2017-06-08 |
2023-01-03 |
Kura Oncology, Inc. |
Methods and compositions for inhibiting the interaction of menin with MLL proteins
|
|
SG11201911859QA
(en)
|
2017-06-16 |
2020-01-30 |
Beta Pharma Inc |
Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof
|
|
IL271946B
(en)
|
2017-07-09 |
2022-09-01 |
Biosight Ltd |
Combination cancer therapy
|
|
TW201920170A
(zh)
*
|
2017-09-20 |
2019-06-01 |
美商庫拉腫瘤技術股份有限公司 |
經取代之menin-mll 抑制劑及使用方法
|
|
GB201720077D0
(en)
|
2017-12-01 |
2018-01-17 |
Univ Oxford Innovation Ltd |
Leukaemic stem cell
|
|
JP7307729B2
(ja)
|
2017-12-20 |
2023-07-12 |
ヤンセン ファーマシューティカ エヌ.ベー. |
メニン-mll相互作用のエキソ-アザスピロ阻害剤
|
|
US11396517B1
(en)
|
2017-12-20 |
2022-07-26 |
Janssen Pharmaceutica Nv |
Exo-aza spiro inhibitors of menin-MLL interaction
|
|
TWI815954B
(zh)
|
2018-08-27 |
2023-09-21 |
日商住友製藥股份有限公司 |
光學活性氮雜雙環衍生物
|
|
JP2022503792A
(ja)
|
2018-09-26 |
2022-01-12 |
クラ オンコロジー,インク. |
メニン阻害剤を用いた血液悪性腫瘍の処置
|
|
JP7594787B2
(ja)
|
2018-12-07 |
2024-12-05 |
ユニバーシティ オブ メリーランド、ボルチモア |
非ATP/触媒部位p38マイトジェン活性化プロテインキナーゼ阻害剤
|
|
TW202104207A
(zh)
|
2019-04-17 |
2021-02-01 |
美商健生生物科技公司 |
二氫乳清酸脫氫酶抑制劑
|
|
JP7319395B2
(ja)
|
2019-06-14 |
2023-08-01 |
ディスアーム セラピューティクス, インコーポレイテッド |
Sarm1の阻害剤
|
|
KR102924600B1
(ko)
|
2019-12-18 |
2026-02-09 |
솔루스첨단소재 주식회사 |
유기 화합물 및 이를 이용한 유기 전계 발광 소자
|
|
UY38988A
(es)
|
2019-12-19 |
2021-06-30 |
Janssen Pharmaceutica Nv |
Derivados espiráncos sustituidos de cadena lineal
|
|
CN111297863B
(zh)
|
2020-03-30 |
2021-06-25 |
四川大学华西医院 |
menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用
|
|
IL297039A
(en)
|
2020-04-07 |
2022-12-01 |
Syndax Pharmaceuticals Inc |
Combinations of menin inhibitors and cyp3a4 inhibitors and methods of use thereof
|
|
WO2022114164A1
(ja)
|
2020-11-30 |
2022-06-02 |
アステラス製薬株式会社 |
ヘテロアリールカルボキシアミド化合物
|
|
EP4334310A1
(en)
|
2021-05-08 |
2024-03-13 |
JANSSEN Pharmaceutica NV |
Substituted spiro derivatives
|
|
BR112023021040A2
(pt)
|
2021-05-08 |
2024-02-06 |
Janssen Pharmaceutica Nv |
Derivados espiro substituídos
|
|
AU2022274071A1
(en)
|
2021-05-11 |
2024-01-04 |
Janssen Pharmaceutica Nv |
Combination therapies
|
|
KR20240006638A
(ko)
|
2021-05-11 |
2024-01-15 |
얀센 파마슈티카 엔브이 |
조합 요법
|
|
JP2024520900A
(ja)
|
2021-05-12 |
2024-05-27 |
シンダックス ファーマシューティカルズ, インコーポレイテッド |
癌の治療のための組合せ
|
|
CA3218479A1
(en)
|
2021-06-01 |
2022-12-08 |
Wei Cai |
Substituted phenyl-1h-pyrrolo[2, 3-c]pyridine derivatives
|
|
WO2022253289A1
(en)
|
2021-06-03 |
2022-12-08 |
Janssen Pharmaceutica Nv |
Pyridazines or 1,2,4-triazines substituted by spirocyclic amines
|
|
AU2022292697A1
(en)
|
2021-06-17 |
2024-02-01 |
Janssen Pharmaceutica Nv |
(r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer
|
|
EP4271676B1
(en)
*
|
2021-12-03 |
2026-07-01 |
Les Laboratoires Servier |
DIAZASPIRO CARBONYL SUBSTITUTE COMPOUNDS AND THEIR USE
|
|
MX2024007201A
(es)
|
2021-12-15 |
2024-08-06 |
Dana Farber Cancer Inst Inc |
Direccionamiento terapeutico del tumor del estroma gastrointestinal (gist) mediante la alteracion del complejo epigenetico de menina-mll.
|
|
WO2023150635A1
(en)
*
|
2022-02-04 |
2023-08-10 |
Kura Oncology, Inc. |
Treatment of hematological malignancies with menin inhibitors and p-glycoprotein inhibitors
|
|
CN120514709A
(zh)
|
2022-05-09 |
2025-08-22 |
赛达克斯制药股份有限公司 |
用于治疗癌症的menin-mll抑制剂
|
|
EP4626885A1
(en)
|
2022-11-30 |
2025-10-08 |
Janssen Pharmaceutica NV |
Cyclobutyl substituted bicyclic compounds
|
|
WO2024114658A1
(en)
|
2022-11-30 |
2024-06-06 |
Janssen Pharmaceutica Nv |
Substituted 1-phenyl-3, 4-dihydropyrido [3, 4-d] pyrimidin-2-one derivatives
|
|
JP2025540762A
(ja)
|
2022-11-30 |
2025-12-16 |
ヤンセン ファーマシューティカ エヌ.ベー. |
メニン-mll阻害剤及びbcl-2阻害剤を含む組み合わせ
|
|
JP2025540759A
(ja)
|
2022-11-30 |
2025-12-16 |
ヤンセン ファーマシューティカ エヌ.ベー. |
メニン-mll阻害剤及び少なくとも1つの他の治療剤を含む組み合わせ
|
|
KR20250170131A
(ko)
|
2023-04-17 |
2025-12-04 |
얀센 파마슈티카 엔브이 |
조혈 장애를 치료하기 위한 메닌-ll1 억제제, dna 삽입제 및 피리미딘 유사체의 조합물
|